SCHEMBL807977

SCHEMBL807977

O=C1c2cc(C(F)(F)F)ccc2CCN1c1cnccc1CN1CCCC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.41
HRH3 Q9Y5N1 2/20 0.39
PARP1 P09874 1/20 0.38
PARP10 Q53GL7 1/20 0.38
HTR2A P28223 3/20 0.37
HTR2C P28335 3/20 0.37
HTR2B P41595 1/20 0.36
CYP11B2 P19099 3/20 0.36
CYP19A1 P11511 1/20 0.36
CYP17A1 P05093 3/20 0.36
MGLL Q99685 2/20 0.36
ABHD6 Q9BV23 2/20 0.36
CYP2D6 P10635 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP11B1 P15538 2/20 0.36
PLA2G7 Q13093 1/20 0.36
GAA P10253 1/20 0.36
FAAH O00519 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15471733 0.85 GRIN2B (0.39) HRH3PARP1PARP10CYP11B2CYP19A1
SCHEMBL793438 0.83 CYP17A1 (0.38) PARP1PARP10HTR2AHTR2CHTR2B
SCHEMBL793423 0.82 PARP1 (0.43) PARP1PARP10HTR2AHTR2CHTR2B
SCHEMBL793449 0.81 PARP1 (0.42) PARP1PARP10HTR2AHTR2CHTR2B
SCHEMBL797906 0.79 PARP1 (0.41) PARP1PARP10HTR2AHTR2CHTR2B
SCHEMBL793796 0.78 CYP17A1 (0.58) CYP17A1
SCHEMBL797817 0.77 CYP11B2 (0.39) PARP1PARP10HTR2AHTR2CHTR2B
SCHEMBL27901786 0.76 MAOA (0.37) MAOAHTR2AHTR2CCYP17A1MGLL
SCHEMBL793346 0.74 CYP11B2 (0.61) PARP1PARP10HTR2AHTR2CHTR2B
SCHEMBL798056 0.73 CYP11B1 (0.47) PARP1PARP10HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
CN-103108871-B 17a-hydroxylase/c17,20-lyase inhibitors NOVARTIS AG 2014-09-10 CN disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 MAOA 354/4885HRH3 656/4885PARP1 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.